Follow Us On : 
Investor Relations
Home 
Investor Relations
Press Release
- Press Release dated 10th March, 2023 -- Marksans Pharma Limited
announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg.
- Press Release – Q3FY23
- Press Release dated 23rd January, 2023- Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
- Press Release dated 20th January, 2023 - Marksans Pharma raises Rs. 372.40 crores in equity via conversion of warrants issued to OrbiMed and the Promoter
- Press Release - Q2FY23
- Press Release dated 11th October, 2022 - Marksans acquires capacity from Tevapharm India
- Press release dated 13th August, 2022 – Q1FY23 Financial Results
- US FDA approval for Pregabalin Capsules, 25 mg, 50 mg,75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg ANDA
- Press Release dated 21.06.2022
- Marksans Pharma signs agreement to acquire 100% stake in Dubai-based Access Healthcare for
Medical Products L.L.C - UK MHRA approval for Bells Healthcare All in One Oral Solution
- US FDA final approval for Cetirizine Hydrochloride Tablets 5mg and 10mg
- UK MHRA approval for Loperamide 2mg Hard Capsules
- News Release November 2021
- USFDA approval for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC)
- News Release August 2021
- News Release May 2021
- News Release September 2020
- Metformin Hydrochloride Extended Release Tablets, USP 500 mg & 750 mg
- News Release June 2020
- Clarification on news circulating through WhatsApp
- Metformin Extended Release Tablets 500 mg
- News Release March 2020
- Metformin Extended Release Tablets 500 mg & 750 mg
- News Release December 2019
- News Release September 2019
- News Release June 2019
- Receipt of Establishment Inspection Report (EIR) from the US FDA
- Performance Highlight – Consolidated Q4 2018-19
- US FDA Audit Update
- Performance Highlight - Consolidated Q3 2018-19
- Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine
5mg / 5ml Oral Solution - Performance Highlight – Consolidated for H1 2018-19
- Performance Highlight – Consolidated Q1 2018-19
- Transfer of Shares in dematerialised form only
- Performance Highlight – Consolidated Q4 2017-18
- Performance Highlight – Consolidated Q3 2017-18
- Performance Highlight - Consolidated for H1 2017-18
- Performance Highlight - Consolidated Q1 2017-18
- Receipt of Establishment Inspection Report
- Performance Highlights - Consolidated
- Marksans Pharma Limited - US FDA
- Marksans Pharma Limited Announcement
- Performance Highlights - Consolidated
- Performance Highlights - Consolidated
- Performance Highlights - Consolidated
- Performance Highlights - Consolidated
- Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended Release
- News Release March 2016
- News Release February 2016
- News Release January 2016
- News Release November 2015
- News Release August 2015
- News Release June 2015
- News Release May 2015
- News Release February 2015
- News Release September 2014
- Proceedings of 22nd AGM
- Report of the Scrutinizer
- Addendum to Notice of 22nd Annual General Meeting
- News Release June 14
© Copyright 2013 Marksans Pharma.